Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Post Transplant Study
Completed
- Conditions
- Kidney TansplantSecondary HyperparathyroidismHyperparathyroidism
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00395902
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Phase 4
Completed
- Conditions
- Vascular CalcificationCalcificationKidney DiseaseNephrologyChronic Kidney DiseaseCoronary Artery CalcificationCardiovascular DiseaseChronic Renal FailureEnd Stage Renal DiseaseSecondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 360
- Registration Number
- NCT00379899
Study of Transitioning From Alendronate to Denosumab
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 504
- Registration Number
- NCT00377819
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
Phase 2
Terminated
- Conditions
- Advanced Non-squamous NSCLC
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 186
- Registration Number
- NCT00369070
Long-Term Assessment of Safety and Physical Function With AMG 108 in RA
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 690
- Registration Number
- NCT00369473
STAAR-1 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2000
- Registration Number
- NCT00369772
STAAR-2 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 618
- Registration Number
- NCT00368901
STAAR-3 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 443
- Registration Number
- NCT00369733
STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
Phase 3
Terminated
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 51
- Registration Number
- NCT00364845
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFOX regimen
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1183
- Registration Number
- NCT00364013
© Copyright 2025. All Rights Reserved by MedPath